Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM52D3)

Drug Name

2-(methylsulfonylthio)ethyl 2-propylpentanoate Drug Info

Synonyms

CHEMBL271677; 2-(methylsulfonylthio)ethyl 2-propylpentanoate; SCHEMBL4156413

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 24759251
TTD Drug ID: DMM52D3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Approved Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histone deacetylase 6 (HDAC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citarinostat	DMQLODU	Multiple myeloma	2A83	Phase 1	[2]
KA2507	DMW0H9Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 8 (HDAC8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NBM-BMX	DM5OWXA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 2 (HDAC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHR-3996	DMIXPNG	Lymphoma	2A80-2A86	Phase 1/2	[5]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 4 (HDAC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-61	DMXH1G3	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-45a	DM5LYKR	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[7]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[2]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[8]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[9]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[10]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[2]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[12]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[14]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[15]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[14]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[13]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[16]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[17]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[10]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[18]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[14]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 10 (HDAC10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-8	DM7YQJK	N. A.	N. A.	Patented	[3]
PSAMMAPLIN A	DM6T0IQ	Discovery agent	N.A.	Investigative	[20]
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	DMVBCID	Discovery agent	N.A.	Investigative	[20]
7-Mercapto-heptanoic acid phenylamide	DM4912P	Discovery agent	N.A.	Investigative	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1]
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[1]
Histone deacetylase 10 (HDAC10)	TTYHPU6	HDA10_HUMAN	Inhibitor	[1]
Histone deacetylase 2 (HDAC2)	TTSHTOI	HDAC2_HUMAN	Inhibitor	[1]
Histone deacetylase 4 (HDAC4)	TTTQGH8	HDAC4_HUMAN	Inhibitor	[1]
Histone deacetylase 6 (HDAC6)	TT5ZKDI	HDAC6_HUMAN	Inhibitor	[1]
Histone deacetylase 8 (HDAC8)	TTT6LFV	HDAC8_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
4	Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
5	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
6	Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
7	Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
10	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
11	US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
12	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
13	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
14	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
15	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
16	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
17	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
18	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
19	2011 Pipeline of 4SC AG.
20	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
21	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.